Search Results

Duralastic Nasal implants are intended for use in augmentation and reconstruction of the nasal contour during rhinoplasty. They are intended for insertion via an intraoral or nasal sill incision.

To augment or reconstruct the nasal contour

Duralastic Nasal implants are "L" shaped or straight with concave convex dorsal aspect which reached from the alar catilage to the radix. These silicone elastomer rubber implants are made from specially formulated silicone elastomers designed for implantation. The LSR 30 Implant Grade elastomer is Masterfiled at FDA and has been thoroughly tested for biocompatibility, mutagenicity, carcinogenicity, and cytotoxicity. These referenced material characterizations are found in Applied Silicone's Master File MAF-562 and Nusil Technologies's MAF 612 for their MED 4211 Silicone Rubber -Unrestricted. The Duralastic Nasal Implants will be provided sterile and nonsterile. Several biocompatible pigments are used to make the white and flesh tone versions of these implants.

I am sorry, but the provided text does not contain the information required to answer your request regarding acceptance criteria and a study proving a device meets them. The document is a 510(k) summary for Duralastic Nasal Implants from 1997, and it focuses on product description, substantial equivalence to a predicate device, intended use, physical/chemical properties, sterilization, and packaging. It also includes the FDA's clearance letter.

Specifically, the document does not include:

• A table of acceptance criteria and reported device performance.
• Details about any specific study (clinical or otherwise) designed to prove the device meets acceptance criteria.
• Information on sample sizes, data provenance, expert ground truth establishment, adjudication methods, MRMC studies, standalone algorithm performance, or ground truth types, as these are typically associated with performance evaluations of diagnostic or AI-driven devices, not simply material properties and substantial equivalence claims for an implantable medical device like this one.

Ask a specific question about this device

The Daralastic Anatomical Nasal Implants are intended to be used to augment or reconstruct the nasal bridge and nasal profile for cosmetic or reconstructive surgery.

Duralastic Nasal implants are "L" shaped or straight with concave convex dorsal aspect which reached from the alar catilage to the radix. These silicone elastomer rubber implants are made from specially formulated silicone elastomers designed for implantation. The LSR 30 Implant Grade elastomer is Masterfiled at FDA and has thoroughly tested for biocompatibility, mutagenicity, carcinogenicity, and cytotoxicity. These referenced material characterizations are found in Applied Silicone's Master File MAF-562. The Duralastic Nasal Implants will be provided sterile and nonsterile. Several biocompatible pigments are used to make the white and flesh tone versions of these implants.

The provided text describes a 510(k) premarket notification for Duralastic Nasal Implants, focusing on their substantial equivalence to previously cleared devices. It does not contain information typically found in a study proving a device meets acceptance criteria, such as specific performance metrics, test methodologies, or statistical analyses. The document is primarily concerned with regulatory approval based on material equivalence and intended use.

Therefore, many of the requested details about acceptance criteria, study design, and performance are not available in the provided text.

Based on the available information, here's what can be extracted:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state acceptance criteria in the form of performance metrics for the device’s clinical efficacy or safety, nor does it report specific device performance results from a study designed to meet such criteria.

The "physical properties" listed can be considered inherent characteristics of the material used, not performance criteria from a clinical study.

2. Sample size used for the test set and the data provenance

Not applicable. The document describes a regulatory submission based on substantial equivalence, not a clinical performance study with a test set of patient data. The biocompatibility, mutagenicity, carcinogenicity, and cytotoxicity are mentioned as "thoroughly tested" material characterizations referenced in a Master File (MAF-562), but no sample sizes or data provenance for these tests are provided in this K971481 submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. This information pertains to studies establishing clinical performance, which is not detailed in this regulatory submission.

4. Adjudication method for the test set

Not applicable. There is no described test set requiring adjudication in this document.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a silicone implant, not an AI-assisted diagnostic tool.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This device is a silicone implant, not an algorithm.

7. The type of ground truth used

For the material properties (biocompatibility, etc.), the "ground truth" would be established through specific laboratory tests and assays designed to evaluate these characteristics, as per the standards referenced (e.g., those implicitly followed for MAF-562). For sterility, the ground truth is established through validation of the sterilization cycle according to ANSI/AAMI/ISO 1137-1994.

8. The sample size for the training set

Not applicable. This information is relevant for machine learning models, not for this type of medical device submission.

9. How the ground truth for the training set was established

Not applicable. This information is relevant for machine learning models, not for this type of medical device submission.

Summary of what the document focuses on:

The document primarily focuses on establishing Substantial Equivalence (SE) to a predicate device (Applied Biomedical nasal implants, previously cleared under K952705). This means that instead of conducting new clinical trials to prove safety and effectiveness, the manufacturer argues that their device is as safe and effective as a legally marketed device due to similar technology, materials, and intended use.

Key arguments for SE:

• Same molds and materials: The Duralastic nasal implants use the "very same molds and materials" as the Applied Biomedical nasal implants.
• Material Characterization: The silicone elastomer (LSR 30 Implant Grade) and pigments are supported by a Master File (MAF-562) which details their biocompatibility, mutagenicity, carcinogenicity, and cytotoxicity tests.
• Intended Use: The intended use for augmentation and reconstruction of the nasal contour is consistent.
• Sterilization: The sterilization process (gamma radiation) is validated according to recognized standards (ANSI/AAMI/ISO 1137-1994).

In essence, the "proof" the device meets acceptance criteria is primarily through its similarity to a previously approved device and the established safety of its constituent materials and sterilization process, rather than a standalone clinical study detailed within this summary.

Ask a specific question about this device